AVB-S6-500 in patients with advanced or metastatic clear cell renal cell carcinoma

What is the Purpose of this Study?

If you choose to join this study, you will:
- Have imaging tests (CT and/or MRI)
- Have blood draws
- Give urine samples
- Be assigned to 1 of 3 study groups
-- One group will take the study drug alone
-- Another group will take the study drug in combination with cabozantinib
-- The final group will take the study drug in combination with cabozantinib + nivolumab

Your study group assignment will depend on what treatments you have previously received for your cancer.

The study drug and cabozantinib are pills that are taken by mouth every day. Nivolumab is given intravenously (through a needle in a vein in your arm) every 2 or 4 weeks, depending on what the study doctor thinks is appropriate.
What is the Condition Being Studied?
Advanced or Metastatic Clear Cell Renal Cell Carcinoma (RCC)

Who Can Participate in this Study?

Adults ages 18+ who:

- Are diagnosed with advanced or metastatic RCC

- Have not received any treatment for RCC yet; OR

- Have received only 1 previous treatment for RCC

For more information about who can join this study, please contact the study team at julia.hurrelbrink@duke.edu

Age Group
Participating Institutions

What is Involved?

We are doing this study to find out if an investigational drug called AVB-S6-500 (the study drug) is a safe and effective treatment for advanced or metastatic clear cell RCC. The study drug may work by preventing cancer cells from invading other parts of the body. People who join this study may or may not receive other cancer drugs in combination with the study drug.

Study Details

Full Title
A phase 1b/2 study of AVB-S6-500 in combination with cabozantinib, AVB-S6-500 in combination with cabozantinib and nivolumab, and AVB-S6-500 monotherapy in patients with advanced of metastatic clear cell renal cell carcinoma
Principal Investigator

Protocol Number

View on ClinicalTrials.gov